Candriam Luxembourg S.C.A. Buys 2,983 Shares of Mazor Robotics Ltd. (MZOR)
Candriam Luxembourg S.C.A. grew its stake in Mazor Robotics Ltd. (NASDAQ:MZOR) by 1.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 159,052 shares of the medical instruments supplier’s stock after purchasing an additional 2,983 shares during the period. Candriam Luxembourg S.C.A. owned approximately 0.62% of Mazor Robotics worth $7,852,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in shares of Mazor Robotics in the second quarter valued at approximately $135,000. JPMorgan Chase & Co. increased its holdings in shares of Mazor Robotics by 398.5% in the first quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock valued at $208,000 after purchasing an additional 5,579 shares during the period. Halbert Hargrove Russell LLC acquired a new position in shares of Mazor Robotics in the third quarter valued at approximately $214,000. BB&T Securities LLC acquired a new position in shares of Mazor Robotics in the second quarter valued at approximately $248,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Mazor Robotics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock valued at $296,000 after purchasing an additional 641 shares during the period. 25.53% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics in a report on Tuesday, November 7th. TheStreet raised Mazor Robotics from a “d” rating to a “c-” rating in a report on Wednesday. Zacks Investment Research lowered Mazor Robotics from a “hold” rating to a “sell” rating in a report on Thursday. Ladenburg Thalmann Financial Services set a $67.00 price objective on Mazor Robotics and gave the stock a “buy” rating in a report on Monday, October 30th. Finally, Barclays PLC lowered Mazor Robotics from an “equal weight” rating to an “underweight” rating and dropped their price objective for the stock from $55.00 to $34.00 in a report on Thursday, October 19th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company’s stock. Mazor Robotics presently has an average rating of “Hold” and an average price target of $39.83.
Mazor Robotics Ltd. (MZOR) traded down $0.51 during trading on Friday, reaching $59.98. The company’s stock had a trading volume of 417,600 shares, compared to its average volume of 828,834. Mazor Robotics Ltd. has a 12 month low of $20.19 and a 12 month high of $65.97.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.